AL 59412C
Alternative Names: AL-59412CLatest Information Update: 15 Apr 2019
At a glance
- Originator Alcon
- Class Antiglaucomas; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 26 Oct 2015 No development reported - Phase-II for Ocular hypertension in USA (Intravitreous)
- 26 Oct 2015 No development reported - Phase-II for Open angle glaucoma in USA (Intravitreous)